{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:58:44Z","timestamp":1790873924056,"version":"4.1.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1765","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Vusolimogene oderparepvec (Tudriqev \u2013 Replimune), a genetically-modified herpes simplex virus type 1 (HSV-1) oncolytic therapy, has been granted accelerated approval by the FDA for use in combination with the programmed death receptor-1 (PD-1)-blocking antibody nivolumab (Opdivo) for treatment of unresectable advanced cutaneous melanoma in adults who had disease progression on a PD-1-blocking antibody-based regimen. About 30-50% of patients develop primary resistance to anti-PD-1 therapy. The oncolytic viral therapy talimogene laherparepvec (Imlygic) was approved in 2015 for treatment of patients with melanoma recurrence postsurgery.<\/jats:p>","DOI":"10.58347\/tml.2026.1765e","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:03:23Z","timestamp":1790870603000},"page":"e170-e171","source":"Crossref","is-referenced-by-count":0,"title":["Vusolimogene Oderparepvec (Tudriqev) \u2013 An Oncolytic Viral Therapy for Melanoma"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,10,12]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:03:23Z","timestamp":1790870603000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1765e"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":0,"journal-issue":{"issue":"1765","published-online":{"date-parts":[[2026,10,12]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1765e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}